Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SPH-4336 by Shanghai Pharmaceutical Group for Dedifferentiated Liposarcoma: Likelihood of Approval
SPH-4336 is under clinical development by Shanghai Pharmaceutical Group and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData,...
Data Insights
SPH-4336 by Shanghai Pharmaceutical Group for Well Differentiated Liposarcoma: Likelihood of Approval
SPH-4336 is under clinical development by Shanghai Pharmaceutical Group and currently in Phase II for Well Differentiated Liposarcoma. According to...